New drug cocktail aims to control aggressive lung cancer

NCT ID NCT05903092

Recruiting now Disease control Sponsor: Hirva Mamdani Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a combination of two drugs, monalizumab and durvalumab, plus chemotherapy for people with small cell lung cancer. The goal is to see if this mix can keep the cancer from growing longer than standard treatment. About 84 adults with either extensive or limited stage disease will take part. The treatment is given as infusions every few weeks, and participants will be monitored for side effects and cancer progression.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EXTENSIVE-STAGE SMALL CELL LUNG CANCER LIMITED STAGE SMALL-CELL LUNG CANCER SCLC SMALL CELL LUNG CANCER

Contacts and locations

Locations

Indiana University Melvin and Bren Simon Comprehensive Cancer Center
RECRUITING

Indianapolis, Indiana, 46202, United States
Karmanos Cancer Center (Wayne State University)
RECRUITING

Detroit, Michigan, 48201, United States
University of Iowa Hospitals and Clinics
RECRUITING

Iowa City, Iowa, 52242, United States
University of Virginia Health System
RECRUITING

Charlottesville, Virginia, 22908, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.